Cellular Therapies in Chronic Granulomatous Disease

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) has become the main curative treatment in patients with chronic granulomatous disease (CGD). CGD is caused by inherited defects of the phagolysomal NADPH-oxidase, leading to a lifelong propensity for invasive infections and granulomatous inflammation. After successful allogeneic HSCT, chronic infections and inflammation resolve and quality-of-life improves. Favorable long-term outcome after HSCT is dependent on the prevention of primary and secondary graft failure (GF), including falling myeloid donor chimerism (DC) below 10 %, and chronic graft-vs.-host-disease (cGVHD). The risk of GF and GvHD increases with the use of HLA-incompatible donors and this may outweigh the benefits of HSCT, mainly in patients with severe co-morbidities and in asymptomatic patients with residual NADPH-oxidase function. Seventeen scientific papers have reported on a total of 386 CGD-patients treated by HSCT with HLA-matched family/sibling (MFD/MSD), 9/10-/10/10-matched-unrelated volunteer (MUD) and cord blood donors. The median OS/EFS-rate of these 17 studies was 91 and 82%, respectively. The median rates of GF, cGVHD and de-novo autoimmune diseases were 14, 10, and 12%, respectively. Results after MFD/MSD and 10/10-MUD-transplants were rather similar, but outcome in adults with significant co-morbidities and after transplants with 9/10 HLA-MUD were less successful, mainly due to increased GF and chronic GVHD. Transplantation protocols using T-cell depleted haploidentical donors with post-transplant cyclophosphamide or TCR-alpha/beta depletion have recently reported promising results. Autologous gene-therapy after lentiviral transduction of HSC achieved OS/EFS-rates of 78/67%, respectively. Careful retrospective and prospective studies are mandatory to ascertain the most effective cellular therapies in patients with CGD.

Introduction

Chronic granulomatous disease is caused by mutations leading to defects in individual subunits of the phagocyte NADPH-oxidase (gp91phox in X-linked-; p22-, p47-, p67-, p40phox, and EROS in autosomal recessive-CGD) (1–4). The NADPH-oxidase-myeloperoxidase system generates microbicidal oxidants required for host defense and control of inflammation. CGD affects ~1:200,000–250,000 live-births (5–7) and X-linked-CGD accounts for approximately two-thirds of patients. P47phox-mutations are the most common AR-defects. Rarely, female carriers of X-CGD with random X-lyonization of <15% of circulating NADPH-oxidase-producing neutrophils present with CGD-symptoms (7–9). Symptoms comprise of invasive infections and chronic autoinflammatory diseases leading to frequent medical interventions, impaired quality-of-life, and increased morbidity/mortality (10–13). The majority of patients are diagnosed in childhood, while some develop symptoms in adulthood (7, 14, 15). Due to residual NADPH-oxidase activity, patients with AR-p47phox-mutations survive longer than X-CGD-patients (survival >40 years: >80 vs. 55%) (16). The clinical course may be unpredictable even in individuals of families with identical CGD-mutations (17). Short stature, osteoporosis, organ failure, and amyloidosis are long-term complications (18). There is still paucity of data on quality-of-life and emotional health in patients with CGD (11, 12, 14, 19, 20). Today, 90% of children with CGD are reaching adulthood and the transition into adult care is challenging (21, 22).

The infections typically affect lungs, lymph nodes, skin, liver, perianal region, gingiva and bone and are mainly caused by Staphylococcus aureus, Burkholderia cepacia, Nocardia, Serratia marcescens, and Aspergillus species. Klebsiella pneumoniae, Salmonella (7, 23), Mycobacteria (21, 24), Actinomyces, Granulibacter bethesthensis (25–27). Infections caused by Chromobacterium violaceum and B. pseudomallei (28–30) are less frequently encountered. The use of life-long antibacterial prophylaxis with trimethoprim-sulfamethoxazole is recommended. Pulmonary Aspergillus-infections are the leading cause of mortality (31). Anti-fungal prophylaxis, mainly with itraconazole (32, 33), can reduce the incidence of fungal infections, but the emergence of azole-resistant aspergillus species and dematiaceous molds is becoming a clinical challenge (34).

Absent or reduced NADPH-oxidase activity in monocytes/macrophages causes impairment of efferocytosis and autophagy (35, 36). Ineffective apoptotic cell clearance increases the risks of developing autoinflammation (37). Progressive granulomatous lung disease (PGLD), Crohn-like enterocolitis (38, 39) and obstructive genitourinary inflammation (40, 41) are relevant autoinflammatory syndromes and their risk increase steadily during life (14). Initial gastrointestinal involvement without infections has often been misdiagnosed as Crohn‘s disease (38, 39). Treatment of autoinflammation includes steroids (42) and more recently IL1- or TNF-alpha inhibitors to replace steroids, however, all of these drugs bear the risk of increasing the risks for invasive infections (43). Thalidomide (44–46), vedolizumab, ustekinumab (47, 48), as well as pioglitazone (36) can be beneficial to reduce autoinflammation in CGD and regular IFN-gamma injections decrease the incidence of bacterial infections with no impact on the incidence of colitis (21, 49–55).

Before HSCT, screening for infections is mandatory in biopsies of infectious lesions and in bronchoalveolar lavage specimens (14, 56). Steroids added to antimicrobials can accelerate the regression of infectious lesions (42, 57, 58) and can help to avoid extensive surgery (59). Granulocyte-transfusions should be strictly indicated to prevent CMV-transmission and sensitization to blood cell antigens (60–62). The McLeod-blood group should be evaluated in X-CGD-patients to minimize the sensitization against Kx-positive red cell transfusions (63–65).

HSCT MAC-Conditioning (Table 1)

In Europe, the first major survey of the Inborn Errors Working Party of the EBMT reported on 27 patients with CGD who had been transplanted between 1985 and 2000. At HSCT, nine of 27 patients had intractable invasive infections and received antibiotics as well as granulocyte-transfusions (seven of nine). Eighteen of 27 patients were free of infection at HSCT. Seven of the 18 patients without overt infection had signs of active ongoing autoinflammation including enterocolitis and PGLD. Twenty-five of the 27 patients received MSD-transplants (five heterozygous carriers). Two patients with no overt infection or autoinflammation received a MUD-transplant. Conditioning-regimens were mainly myeloablative with full-dose busulfan/cyclophosphamide and mainly without serotherapy (67). Recovery from refractory infection, remission of inflammatory organ dysfunction and catch-up growth were observed (67). Patients without overt autoinflammation/infections had an OS of 100%, whereas patients with ongoing infections at transplant had a TRM of 44% (four of nine) (67). The OS/EFS was 85/81%, respectively. The GF and chronic GVHD rate were 7 and 11%, respectively. The majority of surviving patients had >95% circulating myeloid cells of donor origin. This important paper showed that myeloablative HSCT based on busulfan/cyclophosphamide and no in vivo T-cell depletion was overall efficient in sibling transplants but induced exuberant inflammation in patients suffering from ongoing infections at transplant. The same was observed in a transplantation model in non-infected CGD mice after myeloablative allogeneic HSCT resulting in marked infiltration of the lungs with inflammatory cells, in contrast to normal mice (81). Cultured monocytes from the CGD-mice produced 3-fold TNF-alpha (81), explaining the higher incidence of severe GvHD in patients with pre-existing overt infections treated with HSCT without serotherapy. Myeloablative regimens containing cyclophosphamide were greatly abandoned in Europe after this experience. The authors at that time concluded that all infectious/inflammatory foci had to be detected and treated before HSCT and that HSCT should be mainly restricted to children with MSD/MFD (67).

HSCT With RIC/RTC-Regimens (Table 1)

Almost simultaneously to the above mentioned European experience, the NIH in the USA used for the first time a reduced intensity conditioning (RIC) comprising of non-myeloablative fludarabine/cyclophosphamide followed by in-vitro T-cell depleted grafts. This approach resulted in clearly increased GF-rates (20%), even with the use of matched family/sibling donors (66). Donor-lymphocyte infusions were necessary to prevent falling DC but unfortunately induced severe acute GVHD and resulted in a transplant-related mortality rate of 30% (66, 82). RIC-regimens including melphalan and fludarabine were associated with similarly high GF-rates (30%) (75).

RIC-regimens based on reduced or targeted busulfan, fludarabine and serotherapy were more successful and achieved sufficient myeloablation and clearly lower rates of GF and chronic GVHD (38, 63, 83–85). These busulfan-fludarabine-based RIC-regimens were first used in adult high-risk CGD-patients suffering from invasive Aspergillus-infections and/or enterocolitis using MSD/MFD- or MUD transplants. The OS/EFS rates were 100% in these small initial series (38, 84). Administration of anti-T-cell/thymocyte globulins as well as of a humanized monoclonal anti-CD52 antibody (Campath IH; alemtuzumab) were shown to deplete successfully T-cells and allo-stimulatory dendritic cells (86) of recipient origin. The importance of using serotherapy for in-vivo T-cell depletion to reduce both GF and chronic GVHD after HSCT for CGD became obvious. Viral reactivations after serotherapy were fortunately rare or well manageable rendering clinical HSCT outcomes with MUD-donors vastly similar to MSD/MFD-donors (68, 69, 71).

Busulfan-based RIC-conditioning was further refined by investigating the interindividually variable busulfan clearance and exposure in patients (87, 88). Therapeutic drug monitoring (TDM) helped optimize both safety and efficacy of busulfan-administration. The assessment of the cumulative AUC (cAUC) turned out as an appropriate tool to measure the total busulfan-exposure and -toxicity (87, 89). A 10-year prospective study on 56 pediatric/adult CGD-patients (2/3 high-risk patients) treated with submyeloablative busulfan (half-dose or cAUC 45–65 mg/L × h) yielded, indeed, excellent results. Busulfan-dose adjustments (90) were necessary in 14/44 patients (32%) (63). Immunoablation was achieved with fludarabine and serotherapy including rabbit ATG or alemtuzumab. After a follow-up time of 21 months, the OS/EFS-rates were 93 and 89%, respectively. However, GF could not be abolished and occurred in 5% of patients. The cumulative incidences of grade III–IV acute GVHD and chronic GHVD were low with 4 and 7%, respectively. Stable ≥90% myeloid DC was documented in 93% surviving patients leading to resolution of infectious and inflammatory lesions. Equivalent outcomes were observed between MFD/MSD and MUD rendering matched unrelated donors a good donor choice in the absence of matched sibling donors. Outcomes were not different between 9/10-HLA- (n = 10) and 10/10-matched MUD (n = 25), but the numbers were low. Two fatherhoods were documented after successful HSCT. To further reduce the risk of graft failure with this RIC-regimen, some investigators have narrowed the submyeloablative target of the cumulative AUC of busulfan to 55–65 mg/L × h (83) and have started using busulfan starting doses based on a new body weight-dependent busulfan dosing nomogram (91).

Morillo-Gutierrez et al. (74) showed in a large retrospective European study of the EBMT on 70 CGD-children that HSCT after treosulfan-based conditioning was well tolerated and achieved OS/EFS-rates of 91.4/81.4%, respectively. Treosulfan, an alkylating drug with both myeloablative and immunosuppressive effects, exhibited an overall low acute toxicity in CGD transplants. If used as a single alkylator, treosulfan may be less gonadotoxic than other alkylators, however, there is no study yet available convincingly proving this assumption (92–94). Excellent myeloid DC (>95%) was documented in 80% of surviving patients. With this paper, treosulfan-based RTC was shown to be an alternative conditioning to targeted busulfan-based-RIC, although it remained unclear which treosulfan systemic exposure was more likely to be myeloablative or submyeloablative. Graft failure remained a problem occurring in 12% of the patients (74). Some centers have therefore started to add thiotepa to treosulfan to further reduce the risk of GF (80), probably at the expense of augmented gonadotoxicity (94).

The experience with unrelated 4/6–6/6-HLA-compatible cord blood transplants (CBT) in CGD is scarce, but there are a few examples of successful transplants using cord blood in patients lacking MSD or MUD (72, 95, 96). Due to low HSC-numbers in CB, CBT is usually restricted to patients with low body weight (<20 kg) and viral reactivations may be of concern. CBT usually requires myeloablative and therefore more gonadotoxic conditioning, e.g., busulfan (cAUC 80–100 mg/L × h) or treosulfan/thiotepa, to achieve sufficient myeloid engraftment.

For this review, we have analyzed the results of the two above mentioned major European studies together with 15 other relevant international papers published between 2010 and 2019. We have summarized the results of 386 CGD-patients receiving transplants from mainly MSD/MFD- and MUD-donors in Table 1. The median overall incidences of OS, EFS, graft failure, chronic GVHD and de-novo autoimmune disease in these 17 papers were 92, 81, 14, 9, and 15%, respectively. The most important secondary problems were graft failure including patients with slowly falling myeloid DC <10% (DHR/NBT-tests <10%), de-novo autoimmunity and chronic GVHD. Graft failure or low donor myeloid DC was associated with reappearance of CGD associated symptoms, and chronic GVHD clearly impacted negatively on quality-of-life and life expectancy (Table 1).

HSCT With Haploidentical Donors and Gene-Therapy (Table 2)

Hoenig et al. demonstrated for the first time that haploidentical HSCT was curative CGD (97). They used myeloablative conditioning (full-dosed busulfan, thiotepa and alemtuzumab) and in-vitro selected peripheral HSCs and achieved full donor donor cell engraftment and complete resolution of pulmonary aspergillosis. More recently, haploidentical TCR alpha-beta -/CD19-depleted grafts were shown to successfully achieve myeloid donor cell engraftment without inducing relevant GVHD (103–105). The advantage of these in-vitro T-cell depletion techniques is that chronic GVHD is rare (14, 80, 106). In-vivo T-cell depletion strategies in haploidentical transplants include the use post-transplant cyclophosphamide (PT/CY) (50 mg/kg/day), administered on day+3 and day +4 (107). PT/CY is non-toxic to donor HSCs, but efficiently eliminates activated alloreactive donor-derived CD3+T-cells while sparing resting CD3+T-cells with potential anti-infective properties. The first successful haplo HSCT with PT/CY in CGD was reported in the USA after the administration of targeted busulfan (cAUC 40 mg/L × h), fludarabine, cyclophosphamide and 2 Gy TBI (98). However, in a very recent follow-up paper by Parta et al. on seven patients with CGD a rather high rate of severe GVHD was observed leading to death in two patients (OS and EFS 71%, respectively). The estimated total cumulative of busulfan ranged from 30–52 mg/L × h (2,461–4,250 min × micromol/L × 3 days). They used a protocol with mainly PBSC grafts and sirolimus for GVHD-prophylaxis (101). Patients' age ranged between 14 and 26 years and comprised of mainly adults. Severe grade III acute GVHD were observed in three patients with enterocolitis.

Another currently investigated RTC-protocol is currently used in our institution. It comprises of up-front rabbit ATG (30–40 mg/kg), fludarabine (180 mg/sqm) and targeted busulfan (cAUC 65–75 mg/L × h) followed by haplo-HSCT with PT/CY and GVHD prophylaxis with CSA and MMF (starting at day +5). We believe that both haploidentical HSCT with PT/CY and with antibodies containing magnetic beads are promising alternatives in high-risk patients with CGD when HLA-matched related or unrelated donors are unavailable (105). To further explore the rates of graft failure and cGVHD after haploidentical HSCT comparative studies of both techniques are urgently needed (Table 2).

Autologous gene-therapy (GT) of HSCs leads to partially functional correction of defective phagocytes and is a potentially curative treatment approach in CGD. Graft failure may occur after GT, but the risk of GVHD is zero (102, 108, 109). While early studies with unconditioned transfusions of retrovirally transduced HSCs were unsuccessful (110), autologous infusion of HSCs transduced with a gamma-retroviral vector after busulfan-based myeloablative conditioning helped to successfully engraft 4 CGD-patients (2 adults, 2 children) (109). Approximately 15% of gp91phox-expressing neutrophils had been detectable within the first 5 months after GT leading to resolution of life-threatening invasive fungal infections. Unfortunately, methylation with downregulation of the transduced gene and clonal expansion of transduced myeloid cells due to random viral integrations were observed, leading to activation of endogenous oncogenes and development of MDS with or without monosomy 7. Both children treated with GT survived after subsequent allogeneic HSCT (65), while 2 adult patients died due to secondary MDS and AML, respectively. Recently, nine X-CGD-patients (age 2–27 years) received GT using a self-inactivating lentiviral vector designed to limit the risk of mutagenesis (102). Patients were pretreated with myeloablative busulfan exposures (cAUC 70–75 mg/L × h). Two patients died within 3 months from GT due to severe pulmonary disease and hemorrhage. At 12 months, 6/7 surviving patients demonstrated persistence of sufficiently NADPH-oxidase-expressing neutrophils (16–46%) and stable vector copy numbers. One patient had graft failure with a decline <5% enzyme-producing neutrophils. There was no evidence of clonal dysregulation or transgene silencing. Surviving patients did not develop new CGD-related infections, and six have been able to discontinue antibiotic prophylaxis (OS/EFS >12 mo.: 78/66%, respectively) (Table 2).

Indications for Cellular Therapies Today and Outlook

Traditionally, indications for HSCT in CGD had been the following: (1) > 1 invasive life-threatening infections, (2) non-tolerability of prophylactic drugs, (3) non-compliance, (4) severe autoinflammation, or (5) unavailability of a CGD-experienced physician (14, 21, 22, 111). Due to the above mentioned favorable results, there is nowadays agreement that HLA-matched HSCT is indicated in any CGD-patient with absent NADPH-oxidase enzyme activity (16). Small children with CGD may clearly benefit from 5/6- or 6/6-HLA-matched CBT in experienced centers. Less than 10/10-HLA-MUD should probably not be offered to asymptomatic CGD-patients since the rates of graft failure and chronic GVHD are higher than in completely matched transplants. The indication for HSCT in adults should be carefully assessed by the treating physician, although the results in recent years have been encouraging (38, 63, 67, 78, 84, 112). We believe that haploidentical transplants and GT in X-CGD should only be offered to high-risk CGD-patients suffering from severe infectious and/or autoinflammatory complications with no other treatment alternatives. Ideally, high-risk CGD-patients without matched donors should be prospectively investigated in trials comparing GT vs. haploidentical HSCT.

References

• 1.

  SegalBHLetoTLGallinJIMalechHLHollandSM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine. (2000) 79:170–200. 10.1097/00005792-200005000-00004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2.

  van de GeerANieto-PatlanAKuhnsDBToolAtAriasAABouazizMet al. Inherited p40phox deficiency differs from classic chronic granulomatous disease. J Clin Invest. (2018) 128:3957–75. 10.1172/JCI97116

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3.

  DinauerMC. Chronic granulomatous disease and other disorders of phagocyte function. Hematology Am Soc Hematol Educ Program. (2005) 2005:89–95. 10.1182/asheducation-2005.1.89

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4.

  ThomasDCCharbonnierLMSchejtmanAAldhekriHCoomberELDufficyERet al. EROS/CYBC1 mutations: decreased NADPH oxidase function and chronic granulomatous disease. J Allergy Clin Immunol. (2019) 143:782–5.e781. 10.1016/j.jaci.2018.09.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5.

  AhlinAFasthA. Chronic granulomatous disease - conventional treatment vs. hematopoietic stem cell transplantation: an update. Curr Opin Hematol. (2015) 22:41–5. 10.1097/MOH.0000000000000097

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6.

  WinkelsteinJAMarinoMCJohnstonRBJrBoyleJCurnutteJGallinJIet al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine. (2000) 79:155–69. 10.1097/00005792-200005000-00003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7.

  van den BergJMvan KoppenEAhlinABelohradskyBHBernatowskaECorbeelLet al. Chronic granulomatous disease: the European experience. PLoS ONE. (2009) 4:e5234. 10.1371/journal.pone.0005234

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8.

  MagnaniABrosselinPBeauteJde VergnesNMouyRDebréMet al. Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease. J Allergy Clin Immunol. (2014) 134:655–62.e658. 10.1016/j.jaci.2014.04.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9.

  MarcianoBEZerbeCSFalconeELDingLDeRavinSSDaubJet al. X-linked carriers of chronic granulomatous disease: illness, lyonization, and stability. J Allergy Clin Immunol. (2018) 141:365–71. 10.1016/j.jaci.2017.04.035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10.

  PulvirentiFSangerardiMPlebaniASoresinaAFinocchiAPignataCet al. Health-related quality of life and emotional difficulties in chronic granulomatous disease: data on adult and pediatric patients from italian network for primary immunodeficiency (IPINet). J Clin Immunol. (2020) 40:289–98. 10.1007/s10875-019-00725-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11.

  ColeTSMcKendrickFCantAJPearceMSCaleCMGoldblattDRet al. Cognitive ability in children with chronic granulomatous disease: a comparison of those managed conservatively with those who have undergone hematopoietic stem cell transplant. Neuropediatrics. (2013) 44:230–2. 10.1055/s-0033-1333875

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12.

  ColeTMcKendrickFTitmanPCantAJPearceMSCaleCMet al. Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. J Clin Immunol. (2013) 33:8–13. 10.1007/s10875-012-9758-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13.

  ColeTPearceMSCantAJCaleCMGoldblattDGenneryAR. Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol. (2013) 132:1150–5. 10.1016/j.jaci.2013.05.031

  • CrossRef
  • Google Scholar

• 14.

  GenneryA. Recent advances in understanding and treating chronic granulomatous disease. F1000Res. (2017) 6:1427. 10.12688/f1000research.11789.1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15.

  HollandSSegerRSullivanKE. The chronicles of chronic granulomatous disease. Clin Immunol. (2005) 116:99–100. 10.1016/j.clim.2005.04.001

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16.

  KuhnsDBAlvordWGHellerTFeldJJPikeKMMarcianoBEet al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. (2010) 363:2600–10. 10.1056/NEJMoa1007097

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17.

  RoosD. Chronic granulomatous disease. Br Med Bull. (2016) 118:50–63. 10.1093/bmb/ldw009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18.

  KaltenisPMudenieneVMaknaviciusSSeininD. Renal amyloidosis in a child with chronic granulomatous disease and invasive aspergillosis. Pediatr Nephrol. (2008) 23:831–4. 10.1007/s00467-007-0702-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19.

  ColeTSJonesLKMcGroganPPearceMSFloodTJCantAJet al. Emotional and behavioural difficulties in chronic granulomatous disease. Arch Dis Child. (2012) 97:87. 10.1136/archdischild-2011-300780

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20.

  BattersbyACBragginsHPearceMSMcKendrickFCampbellMBurnsSet al. Health-related quality of life and emotional health in x-linked carriers of chronic granulomatous disease in the United Kingdom. J Clin Immunol. (2019) 39:195–9. 10.1007/s10875-019-00607-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21.

  ThomsenIPSmithMAHollandSMCreechCB. A comprehensive approach to the management of children and adults with chronic granulomatous disease. J Allergy Clin Immunol Pract. (2016) 4:1082–8. 10.1016/j.jaip.2016.03.021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22.

  ConnellyJAMarshRParikhSTalanoJA. Allogeneic hematopoietic cell transplantation for chronic granulomatous disease: controversies and state of the art. J Pediatric Infect Dis Soc. (2018) 7(Suppl_1):S31–9. 10.1093/jpids/piy015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23.

  WolachBGavrieliRde BoerMvan LeeuwenKWolachOGrisaru-SoenGet al. Analysis of chronic granulomatous disease in the kavkazi population in israel reveals phenotypic heterogeneity in patients with the same NCF1 mutation (c.579G>A). J Clin Immunol. (2018) 38:193–203. 10.1007/s10875-018-0475-1

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24.

  BustamanteJAksuGVogtGDe BeaucoudreyLGenelFChapgierAet al. BCG-osis and tuberculosis in a child with chronic granulomatous disease. J Allergy Clin Immunol. (2007) 120:32–8. 10.1016/j.jaci.2007.04.034

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25.

  ReichenbachJLopatinUMahlaouiNBeovicBSilerUZbindenRet al. Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis. (2009) 49:1703–10. 10.1086/647945

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26.

  GreenbergDEShoffnerARZelaznyAMFensterMEZaremberKAStockFet al. Recurrent Granulibacter bethesdensis infections and chronic granulomatous disease. Emerg Infect Dis. (2010) 16:1341–8. 10.3201/eid1609.091800

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27.

  GreenbergDEDingLZelaznyAMStockFWongAAndersonVLet al. A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog. (2006) 2:e28. 10.1371/journal.ppat.0020028

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28.

  TarlowMJLloydJ. Melioidosis and chronic granulomatous disease. Proc R Soc Med. (1971) 64:19–20. 10.1177/003591577106400111

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29.

  Meher-HomjiZMangaloreRPPDRJKYLC. Chromobacterium violaceum infection in chronic granulomatous disease: a case report and review of the literature. JMM Case Rep. (2017) 4:e005084. 10.1099/jmmcr.0.005084

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30.

  RenellaRPerezJMChollet-MartinSSarnackiSFischerABlancheSet al. Burkholderia pseudomallei infection in chronic granulomatous disease. Eur J Pediatr. (2006) 165:175–7. 10.1007/s00431-005-0022-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31.

  HenrietSVerweijPEHollandSMWarrisA. Invasive fungal infections in patients with chronic granulomatous disease. Adv Exp Med Biol. (2013) 764:27–55. 10.1007/978-1-4614-4726-9_3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32.

  SegalBHBarnhartLAAndersonVLWalshTJMalechHLHollandSM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis. (2005) 40:1684–8. 10.1086/430068

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33.

  MouyRVeberFBlancheSDonadieuJBraunerRLevronJCet al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr. (1994) 125(6 Pt 1):998–1003. 10.1016/S0022-3476(05)82023-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34.

  MortensenKLMelladoELass-FlorlCRodriguez-TudelaJLJohansenHKArendrupMC. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother. (2010) 54:4545–9. 10.1128/AAC.00692-10

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35.

  de LucaASmeekensSPCasagrandeAIannittiRConwayKLGresnigtMSet al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci USA. (2014) 111:3526–31. 10.1073/pnas.1322831111

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36.

  Fernandez-BoyanapalliRFFalconeELZerbeCSMarcianoBEFraschSCHensonPMet al. Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment. J Allergy Clin Immunol. (2015) 136:1399–401 e1393. 10.1016/j.jaci.2015.07.034

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37.

  BagaitkarJHuangJZengMYPechNKMonlishDAPerez-ZapataLJet al. NADPH oxidase activation regulates apoptotic neutrophil clearance by murine macrophages. Blood. (2018) 131:2367–78. 10.1182/blood-2017-09-809004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38.

  FreudenbergFWintergerstURoesen-WolffAAlbertMHPrellCStrahmBet al. Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as inflammatory bowel disease. J Allergy Clin Immunol. (2010) 125:943–6.e941. 10.1016/j.jaci.2010.01.035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39.

  SchappiMGSmithVVGoldblattDLindleyKJMillaPJ. Colitis in chronic granulomatous disease. Arch Dis Childhood. (2001) 84:147–51. 10.1136/adc.84.2.147

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40.

  MarcianoBERosenzweigSDKleinerDEAndersonVLDarnellDNAnaya-O'BrienSet al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. (2004) 114:462–8. 10.1542/peds.114.2.462

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41.

  De RavinSSNaumannNRobinsonMRBarronKSKleinerDEUlrickJet al. Sarcoidosis in chronic granulomatous disease. Pediatrics. (2006) 117:e590–5. 10.1542/peds.2005-1349

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42.

  FreemanAFMarcianoBEAndersonVLUzelGCostasCHollandSM. Corticosteroids in the treatment of severe nocardia pneumonia in chronic granulomatous disease. Pediatr Infect Dis J. (2011) 30:806–8. 10.1097/INF.0b013e318218181d

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43.

  DeffertCOllerosMLHuipingYHerrmannFRZekryDGarciaIet al. TNF-alpha blockade in chronic granulomatous disease-induced hyperinflammation: patient analysis and murine model. J Allergy Clin Immunol. (2011) 128:675–7. 10.1016/j.jaci.2011.04.028

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44.

  NoelNMahlaouiNBlancheSSuarezFCoignard-BiehlerHDurieuIet al. Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: a retrospective case series. J Allergy Clin Immunol. (2013) 132:997–1000.e1001–1004. 10.1016/j.jaci.2013.04.059

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45.

  UzelGOrangeJSPoliakNMarcianoBEHellerTHollandSM. Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis. Clin Infect Dis. (2010) 51:1429–34. 10.1086/657308

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46.

  HahnKJHoNYockeyLKreuzbergSDaubJRumpAet al. Treatment with anakinra, a recombinant IL-1 receptor antagonist, unlikely to induce lasting remission in patients with CGD colitis. Am J Gastroenterol. (2015) 110:938–9. 10.1038/ajg.2015.135

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47.

  HahnLBeggsAWahaibKKodaliLKirkwoodV. Vedolizumab: an integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis. Am J Health Syst Pharm. (2015) 72:1271–8. 10.2146/ajhp140449

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 48.

  ButteMJParkKTLewisDB. Treatment of CGD-associated Colitis with the IL-23 Blocker Ustekinumab. J Clin Immunol. (2016) 36:619–20. 10.1007/s10875-016-0318-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49.

  FrazaoJBColomboMSimillionCBilicanAKellerIWüthrichDet al. Gene expression in chronic granulomatous disease and interferon-gamma receptor-deficient cells treated in vitro with interferon-gamma. J Cell Biochem. (2019) 120:4321–32. 10.1002/jcb.27718

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50.

  Fernandez-BoyanapalliRMcPhillipsKAFraschSCJanssenWJDinauerMCRichesDWet al. Impaired phagocytosis of apoptotic cells by macrophages in chronic granulomatous disease is reversed by IFN-gamma in a nitric oxide-dependent manner. J Immunol. (2010) 185:4030–41. 10.4049/jimmunol.1001778

  • CrossRef
  • Google Scholar

• 51.

  MouyRSegerRBourquinJPVeberFBlancheSGriscelliCet al. Interferon gamma for chronic granulomatous disease. N Engl J Med. (1991) 325:1516–7. 10.1056/NEJM199111213252115

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52.

  EzekowitzRASieffCADinauerMCNathanDGOrkinSHNewburgerPE. Restoration of phagocyte function by interferon-gamma in X-linked chronic granulomatous disease occurs at the level of a progenitor cell. Blood. (1990) 76:2443–8. 10.1182/blood.V76.12.2443.2443

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53.

  AlimchandaniMLaiJPAungPPKhanguraSKamalNGallinJIet al. Gastrointestinal histopathology in chronic granulomatous disease: a study of 87 patients. Am J Surg Pathol. (2013) 37:1365–72. 10.1097/PAS.0b013e318297427d

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 54.

  YangYXiangZErtlHCWilsonJM. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA. (1995) 92:7257–61. 10.1073/pnas.92.16.7257

  • CrossRef
  • Google Scholar

• 55.

  EzekowitzRADinauerMCJaffeHSOrkinSHNewburgerPE. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med. (1988) 319:146–51. 10.1056/NEJM198807213190305

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 56.

  GungorTEngel-BicikIEichGWilliUVNadalDHossleJPet al. Diagnostic and therapeutic impact of whole body positron emission tomography using fluorine-18-fluoro-2-deoxy-D-glucose in children with chronic granulomatous disease. Arch Dis Child. (2001) 85:341–5. 10.1136/adc.85.4.341

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 57.

  StraughanDMMcLoughlinKCMullinaxJEMarcianoBEFreemanAFAndersonVLet al. The changing paradigm of management of liver abscesses in chronic granulomatous disease. Clin Infect Dis. (2018) 66:1427–34. 10.1093/cid/cix1012

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 58.

  SiddiquiSAndersonVLHilligossDMAbinunMKuijpersTWMasurHet al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis. (2007) 45:673–81. 10.1086/520985

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 59.

  LeidingJWFreemanAFMarcianoBEAndersonVLUzelGMalechHLet al. Corticosteroid therapy for liver abscess in chronic granulomatous disease. Clin Infect Dis. (2012) 54:694–700. 10.1093/cid/cir896

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 60.

  MarcianoBEAllenESConry-CantilenaCKristosturyanEKleinHGFleisherTAet al. Granulocyte transfusions in patients with chronic granulomatous disease and refractory infections: The NIH experience. J Allergy Clin Immunol. (2017) 140:622–5. 10.1016/j.jaci.2017.02.026

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 61.

  HeimKFFleisherTAStroncekDFHollandSMGallinJIMalechHLet al. The relationship between alloimmunization and posttransfusion granulocyte survival: experience in a chronic granulomatous disease cohort. Transfusion. (2011) 51:1154–62. 10.1111/j.1537-2995.2010.02993.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 62.

  ShigemuraTNakazawaYYoshikawaKHirabayashiKSaitoSKobayashiNet al. Successful cord blood transplantation after repeated transfusions of unmobilized neutrophils in addition to antifungal treatment in an infant with chronic granulomatous disease complicated by invasive pulmonary aspergillosis. Transfusion. (2014) 54:516–21. 10.1111/trf.12325

  • CrossRef
  • Google Scholar

• 63.

  GungorTTeiraPSlatterMStussiGStepenskyPMoshousDet al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. (2014) 383:436–48. 10.1016/S0140-6736(13)62069-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 64.

  PartaMKellyCKwatemaaNTheobaldNHilligossDQinJet al. Allogeneic reduced-intensity hematopoietic stem cell transplantation for chronic granulomatous disease: a single-center prospective trial. J Clin Immunol. (2017) 37:548–58. 10.1007/s10875-017-0422-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 65.

  SilerUParuzynskiAHoltgreve-GrezHKuzmenkoEKoehlUD RennerEet al. Successful combination of sequential gene therapy and rescue allo-HSCT in two children with X-CGD - importance of timing. Curr Gene Ther. (2015) 15:416–27. 10.2174/1566523215666150515145255

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 66.

  HorwitzMEBarrettAJBrownMRCarterCSChildsRGallinJIet al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med. (2001) 344:881–8. 10.1056/NEJM200103223441203

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 67.

  SegerRAGungorTBelohradskyBHBlancheSBordigoniPDi BartolomeoPet al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood. (2002) 100:4344–50. 10.1182/blood-2002-02-0583

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 68.

  SchuetzCHoenigMGatzSSpethFBenninghoffUSchulzAet al. Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease. Immunol Res. (2009) 44:35–41. 10.1007/s12026-008-8068-3

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 69.

  SonciniESlatterMAJonesLBHughesSHodgesSFloodTJet al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol. (2009) 145:73–83. 10.1111/j.1365-2141.2009.07614.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 70.

  GozdzikJPituch-NoworolskaASkoczenSCzogalaWWedrychowiczABaranJet al. Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease–single centre experience. J Clin Immunol. (2011) 31:332–7. 10.1007/s10875-011-9513-y

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 71.

  MartinezCAShahSShearerWTRosenblattHMPaulMEChinenJet al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. (2012) 129:176–83. 10.1016/j.jaci.2011.10.005

  • CrossRef
  • Google Scholar

• 72.

  TewariPMartinPLMendizabalAParikhSHPageKMDriscollTAet al. Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. Biol Blood Marrow Transplant. (2012) 18:1368–77. 10.1016/j.bbmt.2012.02.002

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 73.

  AhlinAFugelangJde BoerMRingdenOFasthAWiniarskiJ. Chronic granulomatous disease-haematopoietic stem cell transplantation versus conventional treatment. Acta Paediatr. (2013) 102:1087–94. 10.1111/apa.12384

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 74.

  Morillo-GutierrezBBeierRRaoKBurroughsLSchulzAEwinsAMet al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. (2016) 128:440–8. 10.1182/blood-2016-03-704015

  • CrossRef
  • Google Scholar

• 75.

  KhandelwalPBleesingJJDaviesSMMarshRA. A single-center experience comparing alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning with myeloablative busulfan, cyclophosphamide, and antithymocyte globulin for chronic granulomatous disease. Biol Blood Marrow Transplant. (2016) 22:2011–8. 10.1016/j.bbmt.2016.08.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 76.

  OsumiTTomizawaDKawaiTSakoMInoueETakimotoTet al. A prospective study of allogeneic transplantation from unrelated donors for chronic granulomatous disease with target busulfan-based reduced-intensity conditioning. Bone Marrow Transplant. (2019) 54:168–72. 10.1038/s41409-018-0271-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 77.

  YanirADHansonICShearerWTNoroskiLMForbesLRSeeborgFOet al. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. (2018) 24:1643–50. 10.1016/j.bbmt.2018.03.029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 78.

  FoxTAChakravertyRBurnsSCarpenterBThomsonKLoweDet al. Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. Blood. (2018) 131:917–31. 10.1182/blood-2017-09-807487

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 79.

  ArnoldDESeifAEJyonouchiSSullivanKEBuninNJHeimallJR. Allogeneic hematopoietic stem cell transplantation in adolescent patients with chronic granulomatous disease. J Allergy Clin Immunol Pract. (2019) 7:1052–4. 10.1016/j.jaip.2018.10.034

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 80.

  LumSHFloodTHambletonSMcNaughtonPWatsonHAbinunMet al. Two decades of excellent transplant survival for chronic granulomatous disease: a supraregional immunology transplant center report. Blood. (2019) 133:2546–9. 10.1182/blood.2019000021

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 81.

  YangSPanoskaltsis-MortariAShuklaMBlazarBRHaddadIY. Exuberant inflammation in nicotinamide adenine dinucleotide phosphate-oxidase-deficient mice after allogeneic marrow transplantation. J Immunol. (2002) 168:5840–7. 10.4049/jimmunol.168.11.5840

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 82.

  JacobsohnDADuerstRTseWKletzelM. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet. (2004) 364:156–62. 10.1016/S0140-6736(04)16628-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 83.

  GungorT. Favourable outcome in 47 patients with chronic granulomatous disease after busulfan-based reduced toxicity conditioning and allogeneic hematopoietic stem cell transplantation. J Clin Immunol. (2012) 32:138.

  • Google Scholar

• 84.

  GungorTHalterJKlinkAJungeSStumpeKDSegerRet al. Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients. Transplantation. (2005) 79:1596–606. 10.1097/01.TP.0000163466.73485.5E

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 85.

  GungorTAlbertMSchanzUSlatterMGenneryAWaverAet al. Low-dose busulfan/full-dose fludarabine-based reduced-intensity conditioning in 30 high-risk paediatric and adult chronic granulomatous disease patients. Bone Marrow Transplant. (2011) 46:S16. 10.1016/j.bbmt.2009.12.094

  • CrossRef
  • Google Scholar

• 86.

  RatzingerGReaganJLHellerGBusamKJYoungJW. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood. (2003) 101:1422–9. 10.1182/blood-2002-04-1093

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 87.

  BartelinkIHLalmohamedAvan ReijEMDvorakCCSavicRMZwavelingJet al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. (2016) 3:e526–36. 10.1016/S2352-3026(16)30114-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 88.

  HassanMLjungmanPBolmePRingdenOSyruckovaZBekassyAet al. Busulfan bioavailability. Blood. (1994) 84:2144–50. 10.1182/blood.V84.7.2144.2144

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 89.

  BartelinkIHvan ReijEMGerhardtCEVan MaarseveenEMDe WildtAVersluysBet al. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant. (2014) 20:345–53. 10.1016/j.bbmt.2013.11.027

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 90.

  MalarRSjooFRentschKHassanMGungorT. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatric Transplant. (2011) 15:580–8. 10.1111/j.1399-3046.2011.01529.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 91.

  BartelinkIHBoelensJJBrediusRGWangCBieringsMBShawPJet al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. (2012) 51:331–45. 10.2165/11598180-000000000-00000

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 92.

  LeviMStemmerSMSteinJShalgiRBen-AharonI. Treosulfan induces distinctive gonadal toxicity compared with busulfan. Oncotarget. (2018) 9:19317–27. 10.18632/oncotarget.25029

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 93.

  HaskologluSKostel BalSIslamogluCAltunDKendirliTDoguEFet al. Outcome of treosulfan-based reduced-toxicity conditioning regimens for HSCT in high-risk patients with primary immune deficiencies. Pediatr Transplant. (2018) 22:e13266. 10.1111/petr.13266

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 94.

  BoztugHZeccaMSykoraKWVeysPLankesterASlatterMet al. Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Ann Hematol. (2015) 94:297–306. 10.1007/s00277-014-2196-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 95.

  MorioTAtsutaYTomizawaDNagamura-InoueTKatoKArigaTet al. Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. Br J Haematol. (2011) 154:363–72. 10.1111/j.1365-2141.2011.08735.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 96.

  GungorTFraserCDuffnerUSavasanSBallhausenDHauri-HohlMet al. Targeted busulfan conditioning and unrelated cord blood transplantation in pediatric primary immunodeficiencies and neurometabolic diseases other than Hurler's disease. Bone Marrow Transplant. (2015) 50:S467–8.

  • Google Scholar

• 97.

  HoenigMNiehuesTSiepermannKJacobsenEMSchützCFurlanIet al. Successful HLA haploidentical hematopoietic SCT in chronic granulomatous disease. Bone Marrow Transplant. (2014) 49:1337–8. 10.1038/bmt.2014.125

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 98.

  PartaMHilligossDKellyCKwatemaaNTheobaldNMalechHet al. Haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in a patient with chronic granulomatous disease and active infection: a first report. J Clin Immunol. (2015) 35:675–80. 10.1007/s10875-015-0204-y

  • CrossRef
  • Google Scholar

• 99.

  ShahRMElfekyRNademiZQasimWAmroliaPChiesaRet al. T-cell receptor alpha beta(+) and CD19(+) cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. J Allergy Clin Immun. (2018) 141:1417. 10.1016/j.jaci.2017.07.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 100.

  Regueiro-GarciaAFarina-NogueiraSPorto-ArceoJACouselo-SanchezJM. Haploidentical stem cell transplantation in a boy with chronic granulomatous disease. Allergol Immunopathol (Madr). (2018) 46:385–8.

  • Pubmed Abstract
  • Google Scholar

• 101.

  PartaMHilligossDKellyCKwatemaaNTheobaldNZerbeCSet al. Failure to prevent severe graft-versus-host disease in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in chronic granulomatous disease. J Clin Immunol. (2020) 40:619–4. 10.1007/s10875-020-00772-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 102.

  KohnDBBoothCKangEMPaiSYShawKLSantilliGet al. Lentiviral gene therapy for X-linked chronic granulomatous disease. Nat Med. (2020) 26:200–6. 10.1038/s41591-019-0735-5

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 103.

  BalashovDShcherbinaAMaschanMTrakhtmanPSkvortsovaYShelikhovaLet al. Single-center experience of unrelated and haploidentical stem cell transplantation with TCRalphabeta and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant. (2015) 21:1955–62. 10.1016/j.bbmt.2015.07.008

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 104.

  BertainaAMerliPRutellaSPagliaraDBernardoMEMasettiRet al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders. Blood. (2014) 124:822–6. 10.1182/blood-2014-03-563817

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 105.

  KharyaGNademiZLeahyTRDunnJBargeDSchulzAet al. Haploidentical T-cell alpha beta receptor and CD19-depleted stem cell transplant for Wiskott-Aldrich syndrome. J Allergy Clin Immunol. (2014) 134:1199–201. 10.1016/j.jaci.2014.04.041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 106.

  SlatterMARaoKAbd HamidIJNademiZChiesaRElfekyRet al. Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience. Biol Blood Marrow Transplant. (2018) 24:529–36. 10.1016/j.bbmt.2017.11.009

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 107.

  LuznikLBolanos-MeadeJZahurakMChenARSmithBDBrodskyRet al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. (2010) 115:3224–30. 10.1182/blood-2009-11-251595

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 108.

  MalechHLBoothCKangEMPaiSYShawKLSantilliGet al. Lentiviral vector gene therapy for X-linked chronic granulomatous disease corrects neutrophil function. J Clin Immunol. (2019) 39:S45–6.

  • Google Scholar

• 109.

  OttMGSchmidtMSchwarzwaelderKSteinSSilerUKoehlUet al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. (2006) 12:401–9. 10.1038/nm1393

  • CrossRef
  • Google Scholar

• 110.

  MalechHLMaplesPBWhiting-TheobaldNLintonGFSekhsariaSVowellsSJet al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA. (1997) 94:12133–8. 10.1073/pnas.94.22.12133

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 111.

  ChiriacoMSalfaIDi MatteoGRossiPFinocchiA. Chronic granulomatous disease: clinical, molecular, and therapeutic aspects. Pediatr Allergy Immunol. (2016) 27:242–53. 10.1111/pai.12527

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 112.

  ChiesaRWangJFBlokHJNevenBMoshousDSchulzAet al. Allogeneic hematopoietic stem cell transplantation in children and adults with chronic granulomatous disease (CGD): a study of the inborn errors working party (IEWP) of the EBMT. Blood. (2018) 132:970. 10.1182/blood-2018-99-114841

  • CrossRef
  • Google Scholar